A Phase 2, Open-label Study of ABI-009 (Nab-Rapamycin) in Patients With Recurrent High-grade Glioma and Patients With Newly Diagnosed Glioblastoma
Latest Information Update: 09 Nov 2023
At a glance
- Drugs Bevacizumab (Primary) ; Lomustine (Primary) ; Marizomib (Primary) ; Sirolimus (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Glioma
- Focus Therapeutic Use
- Sponsors AADi
- 03 Feb 2023 Status changed from active, no longer recruiting to completed.
- 02 Jun 2021 Status changed from recruiting to active, no longer recruiting.
- 08 Mar 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.